한국간담췌외과학회지 (Annals of Hepato-Biliary-Pancreatic Surgery)

  • 제26권3호
  • /
  • Pages.220-228
  • /
  • 2022
  • /
  • 2508-5778(pISSN)
  • /
  • 2508-5859(eISSN)
한국간담췌외과학회 (The Korean Association of Hepato-Biliary-Pancreatic Surgery)
권호 표지
DOI QR코드

DOI QR Code

Incidence, mortality and survival of gallbladder, extrahepatic bile duct, and pancreatic cancer using Korea central cancer registry database: 1999-2019

  • Mee Joo Kang (Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center) ;
  • E Hwa Yun (Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center) ;
  • Kyu-Won Jung (Division of Cancer Registration and Surveillance, National Cancer Control Institute, National Cancer Center) ;
  • Sang-Jae Park (Center for Liver and Pancreatobiliary Cancer, National Cancer Center)
  • 투고 : 2022.06.09
  • 심사 : 2022.06.18
  • 발행 : 2022.08.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Backgrounds/Aims: In Korea, pancreatic cancer and "gallbladder and extrahepatic bile duct cancer" were ranked the 8th and 9th most frequent cancers in 2019 and the 4th and 6th most common causes of cancer deaths in 2020, respectively. Methods: This review provides national cancer statistics and secular trends of 207,521 patients with gallbladder (n = 44,178), extrahepatic bile duct (n = 61,856), and pancreatic cancer (n = 101,487) between 1999 and 2019 in Korea. Results: The crude incidence rate in both sexes increased in the gallbladder (2.8 to 5.4 per 100,000), extrahepatic bile duct (3.6 to 9.0), and pancreatic cancer (5.5 to 15.8). The age-standardized incidence rate in both sexes significantly increased in the extrahepatic bile duct (3.7 to 4.1) and pancreatic (5.6 to 7.6) cancers but decreased in gallbladder cancer (2.9 to 2.4). The overall 5-year relative survival rate increased in the gallbladder (21.8% to 30.6%), extrahepatic bile duct (23.1% to 27.5%), and pancreatic (8.5% to 13.3%) cancers. Between 2006 and 2019, the proportion of localized or regional stages remained stable. The proportion of surgical treatment within the first 4 months after diagnosis was relatively higher in the gallbladder (42.2%) and extrahepatic bile duct (45.9%) cancers than in pancreatic cancer (22.2%). Conclusions: The crude incidence and mortality rates of the gallbladder, extrahepatic bile duct, and pancreatic cancer are steadily increasing in Korea, and the prognosis remains poor. Early detection, active application of surgical treatment, and minimization of the proportion of untreated patients are required to improve the survival rates of these cancers.

키워드

과제정보

This work was accomplished with collaboration of KAHBPS and the Korea Central Cancer Registry.

참고문헌

  1. Kang MJ, Won YJ, Lee JJ, Jung KW, Kim HJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2019. Cancer Res Treat 2022;54:330-344.
  2. Statistics Korea. 236 causes of death, 2020 [Internet]. Daejeon: Statistics Korea 2022 [cited 2022 May 5]. Available from: https://kosis.kr/statHtml/statHtml.do?orgId=101&tblId=DT_1B34E07&vw_cd=MT_ZTITLE&list_id=F_27&scrId=&seqNo=&lang_mode=ko&obj_var_id=&itm_id=&conn_path=MT_ZTITLE&path=%252FstatisticsList%252FstatisticsListIndex.do.
  3. Korea Central Cancer Registry. Annual report of cancer statistics in Korea in 2019. Goyang: National Cancer Center, 2021.
  4. Statistics Korea. Annual report on the causes of death statistics 2020. Daejeon: Statistics Korea, 2021.
  5. World Health Organization. ICD-10: international statistical classification of diseases and related health problems. 10th rev. Geneva: World Health Organization, 2010.
  6. Hong SY, Kang MJ, Kim T, Jung KW, Kim BW. Incidence, mortality, and survival of liver cancer using Korea central cancer registry database: 1999-2019. Ann Hepatobiliary Pancreat Surg 2022;26:211-219.
  7. National Cancer Institute. SEER training modules [Internet]. Bethesda: U.S. National Institutes of Health, National Cancer Institute 2022 [cited 2022 Apr 17]. Available from: https://training.seer.cancer.gov/.
  8. Kang MJ, Lim J, Han SS, Park HM, Park SJ, Won YJ, et al. First course of treatment and prognosis of exocrine pancreatic cancer in Korea from 2006 to 2017. Cancer Res Treat 2022;54:208-217.
  9. Segi M. Cancer mortality for selected sites in 24 countries (1950-1957). Sendai: Tohoku University School of Medicine, 1960.
  10. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Vol. 10. Bethesda: National Cancer Institute, 1959.
  11. Centers for Disease Control and Prevention. United States cancer statistics: incidence and death rates [Internet]. Atlanta: Centers for Disease Control and Prevention 2022 [cited 2022 May 5]. Available from: https://www.cdc.gov/cancer/uscs/technical_notes/stat_methods/rates.htm.
  12. National Cancer Institute. Surveillance, epidemiology, and end results program: recent trends in seer age-adjusted incidence rates, 2000-2019 [Internet]. Bethesda: National Cancer Institute [cited 2022 May 5]. Available from: https://seer.cancer.gov/statistics-network/explorer/application.html?site=40&data_type=1&graph_type=2&compareby=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&stage=101&advopt_precision=1&advopt_show_ci=on&advopt_display=2.
  13. Kang MJ, Lim JW, Han SS, Park HM, Kim SW, Lee WJ, et al. Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study. Sci Rep 2022;12:10206.
  14. Walter D, Ferstl P, Waidmann O, Trojan J, Hartmann S, Schnitzbauer AA, et al. Cholangiocarcinoma in Germany: epidemiologic trends and impact of misclassification. Liver Int 2019;39:316-323.
  15. Khan SA, Emadossadaty S, Ladep NG, Thomas HC, Elliott P, Taylor-Robinson SD, et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol 2012;56:848-854.
  16. Kang MJ, Lim J, Han SS, Park HM, Kim SW, Won YJ, et al. Impact of changes in the topographic classification of Klatskin tumor on incidence of intra- and extrahepatic bile duct cancer: a population-based national cancer registry study. J Hepatobiliary Pancreat Sci 2021;28:740-750.
  17. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology, 3rd ed, 1st revision [Internet]. Geneva: World Health Organization 2013 [cited 2022 May 19]. Available from: https://apps.who.int/iris/handle/10665/96612.
  18. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology, 3rd ed, 2nd revision [Internet]. Lyon: IARC 2019 [cited 2022 May 19]. Available from: http://www.iacr.com.fr/index.php?option=com_content&view=article&id=149:icd-o-3-2&catid=80&itemid=545.